RespireRx Pharmaceuticals (OTC:RSPI) CFO Jeff Margolis joins Natalie Stoberman in the Proactive studio to talk about entering a letter of intent with an Australian headquartered clinical research organization for Dronabinol development for sleep apnea.
RespireRx Pharmaceuticals Inc. is a leader in the discovery and development of medicines for the treatment of psychiatric and neurological disorders.